ActualitésAssisté par IA

OKYO Pharma’s OK-101 Advances in Phase 2 Trials for Dry Eye and Corneal Pain

OKYO Pharma advances OK-101 for dry eye and neuropathic corneal pain with positive Phase 2 results.

Par Mrudula Kulkarni

Rédacteur en chef - Pharma Now

24 août 2024Updated Jun 26, 2025 · 2 min de lecture

Partager Ajouter comme source préférée

OKYO Pharma’s OK-101 Advances in Phase 2 Trials for Dry Eye and Corneal Pain — https://okyopharma.com/okyo-pharma-limited-announces-u-s-5-74-million-global-private-placement-and-investment-by-directors-and-members-of-senior-management/

Journalisme assisté par IA

Reviewed by Mrudula Kulkarni, Rédacteur en chef - Pharma Now

The biopharmaceutical business OKYO Pharma Limited is making progress in creating therapeutics for two illnesses that now lack viable treatments: neuropathic corneal pain (NCP) and dry eye disease (DED). OK-101, their flagship candidate, has demonstrated encouraging outcomes in Phase 2 studies, with notable reductions in DED symptoms along with a good safety profile. In addition, the business is getting ready to start a Phase 2 trial for OK-101 in the treatment of NCP, emphasising the drug's potential to meet unmet ophthalmic medical requirements.

SujetsActualités

Written by

Mrudula Kulkarni

Rédacteur en chef - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.